secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-06-09T23:59:59+00:00
Accession:  0000950170-25-083866
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage Cell Therapeutics appoints Baker Tilly as auditor after Moss Adams merger
--------------------------------------------------------------------------------

- Moss Adams merged with Baker Tilly effective June 3, 2025; Moss Adams resigned as auditor.
- Audit Committee approved Baker Tilly as successor for fiscal year ending Dec 31, 2025.
- No disagreements or reportable events occurred during the past two fiscal years or interim period.
- Moss Adams' 2024 audit report was unqualified and contained no adverse opinion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025083866/0000950170-25-083866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025083866/lctx-20250603.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-083866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer